Skip to main content
. 2019 Dec 30;9:20350. doi: 10.1038/s41598-019-56617-2

Table 1.

Patient characteristics.

Variable Control HCM HCM P-value
HNCM HOCM Control:HCM HNCM:HOCM
N 53 64 33 31
Age (years) 53.5 ± 13.7 52.6 ± 16.3 49.2 ± 15.4 56.4 ± 16.7 0.748 0.077
Male N (%) 35 (66.0) 41 (64.1) 25 (75.8) 16 (51.6) 0.848 0.068
Body mass index (kg/m2) 26.9 (24.4–30.4) 26.6 (24.1–30.7) 27.3 (24.5–30.0) NA 0.619
Echocardiogram
IVS (mm) 18.0 (16.0–22.0) 17.0 (14.3–22.0) 19.0 (16.0–21.0) NA 0.205
LVEDD (mm) 43. (40.0–48.0) 43.5 (41.0–48.8) 42.0 (38.0–47–0) NA 0.107
Aortic root (mm) 32.0 (28.0–35.0) 32.0 (27.3–35.0) 32.0 (28.8–35.3) NA 0.702
LVPWD (mm) 12.0 (10.0–13.0) 11.0 (9.3–12.0) 12.0 (11.0–15.0) NA 0.053
LVOT gradient (mmHg) 75.5 (12.9–115.5) 9.5 85.5–17.3) 98.5 (74.5–133.3) NA <0.001*
Mitral regurgitation N (%) NA 0.002*
   minor 44 (68.8) 29 (87.9) 15 (48.4)
   medium 12 (18.8) 3 (9.1) 9 (29.0)
   major 5 (7.8) 0 (0.0) 5 (16.1)
   missing 3 (4.7) 1 (3.0) 2 (6.5)
LA size (mm) 42. (37.5–50.5) 40.0 (36.0–49.0) 44.0 (39.8–51.3) NA 0.177
Clinical symptoms
Syncope N (%) 9 (14.1) 2 (9.1) 6 (19.4) NA 0.302
Positive family history for SCD N (%) 18 (28.1) 11 (33.3) 7 (22.6) NA 0.408
Dyspnoea N (%) 34 (53.1) 15 (45.5) 19 (61.3) NA 0.315
NYHA N (%) NA 0.088
   0 1 5 (7.8) 4 (12.1) 1 (3.2)
   1 2 11 (17.2) 8 (24.2) 3 (9.7)
   2 3 29 (45.3) 12 (36.4) 17 (54.8)
   3 4 15 (23.4) 5 (15.2) 10 (32.3)
missing 4 (6.3) 4 (12.1) 0 (0.0)
Angina pectoris N (%) 9 (14.1) 2 (6.1) 7 (22.6) NA 0.082
Palpitations N (%) 23 (35.9) 11 (33.3) 12 (38.7) NA 0.797
Peripheral edema N (%) 9 (14.1) 6 (18.2) 3 (9.7) NA 0.474
Arrhythmias 31 (48.4) 19 (57.6) 12 (38.7) NA 0.204
Atrial Fibrillaton 6 (9.4) 4 (12.1) 2 (6.5) NA 0.672
Mitral valve murmur 26 (40.6) 7 (21.2) 19 (61.3) NA 0.004*
Co-morbidities
Hypertension N (%) 31 (48.4) 17 (51.5) 14 (45.2) NA 0.612
Diabetes mellitus N (%) 6 (9.4) 3 (9.1) 3 (9.7) NA 1.000
Coronary artery disease N (%) 13 (20.3) 5 (15.2) 8 (25.8) NA 0.534
Myocardial infarction 4 (6.3) 2 (6.1) 2 (6.5) NA 1.000
COPD 4 (96.9) 0 (0.0) 4 (12.9) NA 0.113
Drugs
Beta blockers N (%) 50 (78.1) 25 (72.7) 26 (83.9) NA 0.536
ACE inhibitors 19 (29.7) 10 (30.3) 9 (29.0) NA 1.000
AT1 inhibitors 10 (15.6) 9 (27.3) 1 (3.2) NA 0.013*
Diuretics 23 (35.9) 1 (97.0) 13 (41.9) NA 0.439
Calcium antagonists N (%) 18 (28.1) 8 (24.2) 10 (32.3) NA 0.585
Anticoagulation drugs N (%) 32 (50.0) 15 (45.5) 17 (54.8) NA 0.617

Data are presented as frequencies (percentages) for categorical variables. Continuous variables with normal distribution are presented as mean ± standard deviation. Continuous parameters with skewed distributions as median (interquartile range). *Statistically significant. NA: Not applicable.

Data are presented as frequencies (percentage) for categorical variables. Continuous variables with normal distribution are presented as mean ± standard deviation. Continuous parameters with skewed distributions as median (interquartile range)32. HCM: hypertrophic cardiomyopathy; HNCM: non-obstructive hypertrophic cardiomyopathy; HOCM: hypertrophic obstructive cardiomyopathy; NA: Not applicable.

IVS = interventicular septum size; LVEDD = left ventricular end-diastolic diameter; LVPWD = left ventricular posterior wall thickness end diastole; LVOT gradient = left ventricular outflow tract gradient maximum; LA = left atrium; AT1 = angiotensin II receptor antagonist; ACE = angiotensin-converting enzyme; COPD = chronic obstructive pulmonary disease; SCD = sudden cardiac death.